How Rapid Anticipatory Estrogen Activation of the Unfolded Protein Response Acts as an Authorizing Signal for Estrogen Receptor Action

未折叠蛋白反应的快速预期雌激素激活如何作为雌激素受体作用的授权信号

基本信息

项目摘要

Estrogens, acting via estrogen receptor α (ERα), were known to regulate gene expression and to activate signal transduction pathways. We identified a conserved extranuclear pathway by which 17β-estradiol (E2), acting through ERα, rapidly activates phosphoplipase C γ (PLCγ) leading to production of inositol triphosphate (IP3). The IP3 binds to and opens endoplasmic reticulum (EnR) IP3 receptors (IP3R) leading to extremely rapid (<1 min.) efflux of calcium (Ca2+) from the lumen of the EnR into the cell body. Elevated intracellular Ca2+ primes cells for subsequent actions of E2-ERα; depletion of EnR Ca2+ activates the unfolded protein response (UPR), inducing the important chaperone BiP/GRP78 (glucose regulated protein 78 kDa). Activation of this pathway is required for E2-ERα-regulated gene expression, induction of cell proliferation and protects cells against stress. We target this pathway with our medically promising ERα biomodulator, BHPI, which uses the same pathway as E2, but induces toxic hyperactivation of the UPR. Our hypothesis is that the products of activation of this newly unveiled pathway, elevated intracellular calcium (Aim 1), and at later times, BiP chaperone (Aim 2), link to and regulate subsequent E2-ERα-regulated gene expression and stabilize ERα, influencing drug resistance and genomic actions of ERα. Our goals are to identify the mechanism(s) by which these products couple to, and control, gene expression (Aim 1), ERα stability and response to drugs (Aim 2), and to identify the sensors and signals that allow E2-ERα to rapidly initiate the pathway (Aim 3). Aim 1. Identify the mechanism(s) by which the product of E2-ERα activation of the pathway couples to and controls E2-ERα-regulated gene expression. Test the data-driven hypothesis that Ca2+ produced by pathway activation acts through the Ca2+ sensor calmodulin (CaM) to regulate nuclear E2-ERα:CaM interaction, E2-ERα dimerization and nuclear localization and thereby controls E2-ERα-regulated gene expression. Aim 2. Background: In CRISPR/Cas9 generated cell lines expressing constitutively active ERα mutants, the UPR is activated and ERα is partially resistant to antagonists. Identify the mechanism by which UPR activation contributes to drug resistance. Test the hypothesis that drug resistance in these cells arises in part because ERα, together with progesterone-PR, synergistically activate the UPR, inducing BiP chaperone, which stabilizes ERα, thereby contributing to drug resistant gene expression. Aim 3. Identify components of the multiprotein complex by which E2-ERα initiates the pathway. Using an unbiased CRISPR/Cas9 lethality screen, followed by verification and analysis of multiprotein complexes, we will identify the activating kinase(s), scaffolding proteins, other components of the complex(es), genes that impact the pathway and probe ERα interactions in the complex. These studies will establish the initial events that occur when estrogen contacts a cell and identify new mechanisms coupling steroid receptor regulated transcription to extranuclear signals.
已知雌激素通过雌激素受体α (ERα)起作用,调节基因表达和激活

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID J SHAPIRO其他文献

DAVID J SHAPIRO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID J SHAPIRO', 18)}}的其他基金

A Pathway for Necrotic Cell Death
坏死细胞死亡的途径
  • 批准号:
    10680459
  • 财政年份:
    2022
  • 资助金额:
    $ 37.38万
  • 项目类别:
A Pathway for Necrotic Cell Death
坏死细胞死亡的途径
  • 批准号:
    10522435
  • 财政年份:
    2022
  • 资助金额:
    $ 37.38万
  • 项目类别:
Targeting c-Myc and MDR1 in Cancer Through Small Molecule Inhibitors of IMP-1
通过 IMP-1 小分子抑制剂靶向癌症中的 c-Myc 和 MDR1
  • 批准号:
    8688973
  • 财政年份:
    2013
  • 资助金额:
    $ 37.38万
  • 项目类别:
Targeting c-Myc and MDR1 in Cancer Through Small Molecule Inhibitors of IMP-1
通过 IMP-1 小分子抑制剂靶向癌症中的 c-Myc 和 MDR1
  • 批准号:
    8584046
  • 财政年份:
    2013
  • 资助金额:
    $ 37.38万
  • 项目类别:
Targeting Breast Cancer with Small Molecule Inhibitors of Estrogen Receptor
用雌激素受体小分子抑制剂治疗乳腺癌
  • 批准号:
    8448699
  • 财政年份:
    2005
  • 资助金额:
    $ 37.38万
  • 项目类别:
Targeting Breast Cancer with Small Molecule Inhibitors of Estrogen Receptor
用雌激素受体小分子抑制剂治疗乳腺癌
  • 批准号:
    7655786
  • 财政年份:
    2005
  • 资助金额:
    $ 37.38万
  • 项目类别:
Targeting Breast Cancer with Small Molecule Inhibitors of Estrogen Receptor
用雌激素受体小分子抑制剂治疗乳腺癌
  • 批准号:
    8052823
  • 财政年份:
    2005
  • 资助金额:
    $ 37.38万
  • 项目类别:
How Rapid Anticipatory Estrogen Activation of the Unfolded Protein Response Acts as an Authorizing Signal for Estrogen Receptor Action
未折叠蛋白反应的快速预期雌激素激活如何作为雌激素受体作用的授权信号
  • 批准号:
    9915884
  • 财政年份:
    2005
  • 资助金额:
    $ 37.38万
  • 项目类别:
Assays for Estogen and Progesterone Receptor Antagonists
雌激素和孕激素受体拮抗剂的测定
  • 批准号:
    7094064
  • 财政年份:
    2005
  • 资助金额:
    $ 37.38万
  • 项目类别:
Targeting Breast Cancer with Small Molecule Inhibitors of Estrogen Receptor
用雌激素受体小分子抑制剂治疗乳腺癌
  • 批准号:
    8247814
  • 财政年份:
    2005
  • 资助金额:
    $ 37.38万
  • 项目类别:

相似国自然基金

帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 批准年份:
    2021
  • 资助金额:
    58.00 万元
  • 项目类别:
    面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    58 万元
  • 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
  • 批准号:
    31672538
  • 批准年份:
    2016
  • 资助金额:
    62.0 万元
  • 项目类别:
    面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 批准年份:
    2013
  • 资助金额:
    80.0 万元
  • 项目类别:
    面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
  • 批准号:
    81172529
  • 批准年份:
    2011
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
  • 批准号:
    81070952
  • 批准年份:
    2010
  • 资助金额:
    35.0 万元
  • 项目类别:
    面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
  • 批准号:
    30672361
  • 批准年份:
    2006
  • 资助金额:
    24.0 万元
  • 项目类别:
    面上项目

相似海外基金

Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
  • 批准号:
    2321481
  • 财政年份:
    2024
  • 资助金额:
    $ 37.38万
  • 项目类别:
    Continuing Grant
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
  • 批准号:
    2321480
  • 财政年份:
    2024
  • 资助金额:
    $ 37.38万
  • 项目类别:
    Continuing Grant
Postdoctoral Fellowship: OPP-PRF: Understanding the Role of Specific Iron-binding Organic Ligands in Governing Iron Biogeochemistry in the Southern Ocean
博士后奖学金:OPP-PRF:了解特定铁结合有机配体在控制南大洋铁生物地球化学中的作用
  • 批准号:
    2317664
  • 财政年份:
    2024
  • 资助金额:
    $ 37.38万
  • 项目类别:
    Standard Grant
Conformations of musk odorants and their binding to human musk receptors
麝香气味剂的构象及其与人类麝香受体的结合
  • 批准号:
    EP/X039420/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.38万
  • 项目类别:
    Research Grant
NPBactID - Differential binding of peptoid functionalized nanoparticles to bacteria for identifying specific strains
NPBactID - 类肽功能化纳米粒子与细菌的差异结合,用于识别特定菌株
  • 批准号:
    EP/Y029542/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.38万
  • 项目类别:
    Fellowship
Alkane transformations through binding to metals
通过与金属结合进行烷烃转化
  • 批准号:
    DP240103289
  • 财政年份:
    2024
  • 资助金额:
    $ 37.38万
  • 项目类别:
    Discovery Projects
I-Corps: Translation Potential of Real-time, Ultrasensitive Electrical Transduction of Biological Binding Events for Pathogen and Disease Detection
I-Corps:生物结合事件的实时、超灵敏电转导在病原体和疾病检测中的转化潜力
  • 批准号:
    2419915
  • 财政年份:
    2024
  • 资助金额:
    $ 37.38万
  • 项目类别:
    Standard Grant
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
  • 批准号:
    MR/Y013131/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.38万
  • 项目类别:
    Research Grant
CRII: OAC: Development of a modular framework for the modeling of peptide and protein binding to membranes
CRII:OAC:开发用于模拟肽和蛋白质与膜结合的模块化框架
  • 批准号:
    2347997
  • 财政年份:
    2024
  • 资助金额:
    $ 37.38万
  • 项目类别:
    Standard Grant
How lipid binding proteins shape the activity of nuclear hormone receptors
脂质结合蛋白如何影响核激素受体的活性
  • 批准号:
    DP240103141
  • 财政年份:
    2024
  • 资助金额:
    $ 37.38万
  • 项目类别:
    Discovery Projects
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了